Invivyd Yönetim

Yönetim kriter kontrolleri 2/4

Invivyd CEO'su Bill Duke, Sep2023 tarihinde atandı, in görev süresi 2.58 yıldır. in toplam yıllık tazminatı $ 2.14M olup, şirket hissesi ve opsiyonları dahil olmak üzere 22.7% maaş ve 77.3% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.038% ine doğrudan sahiptir ve bu hisseler $ 189.59K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 2.3 yıl ve 2.9 yıldır.

Anahtar bilgiler

Bill Duke

İcra Kurulu Başkanı

US$2.1m

Toplam tazminat

CEO maaş yüzdesi	22.65%
CEO görev süresi	2.6yrs
CEO sahipliği	0.04%
Yönetim ortalama görev süresi	2.3yrs
Yönetim Kurulu ortalama görev süresi	2.9yrs

Son yönetim güncellemeleri

Recent updates

Invivyd: A Logical Bull Thesis With A Major Catalyst Approaching

Mar 20

Invivyd, Inc.'s (NASDAQ:IVVD) 26% Share Price Plunge Could Signal Some Risk

Jan 29

Optimistic Investors Push Invivyd, Inc. (NASDAQ:IVVD) Shares Up 27% But Growth Is Lacking

Nov 29

Invivyd, Inc.'s (NASDAQ:IVVD) Price Is Right But Growth Is Lacking After Shares Rocket 31%

Oct 14

Why Investors Shouldn't Be Surprised By Invivyd, Inc.'s (NASDAQ:IVVD) 31% Share Price Plunge

Aug 22

CEO Tazminat Analizi

Bill Duke'un ücretlendirmesi Invivyd'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Dec 31 2025	US$2m	US$485k	-US$52m
Sep 30 2025	n/a	n/a	-US$60m
Jun 30 2025	n/a	n/a	-US$110m
Mar 31 2025	n/a	n/a	-US$143m
Dec 31 2024	US$636k	US$480k	-US$170m

Tazminat ve Piyasa: Bill 'ın toplam tazminatı ($USD 2.14M ) US pazarındaki benzer büyüklükteki şirketler için ortalamadır ($USD 2.45M ).

Tazminat ve Kazançlar: Bill şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Bill Duke (53 yo)

2.6yrs

Görev süresi

US$2,141,222

Tazminat

Mr. William E. Duke, Jr., also known as Bill, M.B.A., serves as Chief Financial Officer and Principal Accounting Officer of Invivyd, Inc. since September 2023 and serves as its Principal Executive Officer...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
William Duke	CFO, Principal Accounting Officer & Principal Executive Officer	2.6yrs	US$2.14m	0.038% $ 189.6k
Jill Andersen	Chief Legal Officer & Corporate Secretary	4.4yrs	US$2.49m	0.064% $ 320.7k
Timothy Lee	Chief Commercial Officer	1.9yrs	US$2.10m	0.042% $ 207.2k
Robert Allen	Chief Scientific Officer	3yrs	US$2.16m	0.040% $ 201.5k
Scott Young	Senior Vice President of Investor Relations & Corporate Communications	no data	Veri yok	Veri yok
Kristie Kuhl	Chief Communications Officer	less than a year	Veri yok	Veri yok
Julie Green	Chief Human Resources Officer	3.3yrs	US$1.59m	0.038% $ 189.6k
Rachael Gerlach	Senior Vice President of Regulatory Affairs	less than a year	Veri yok	Veri yok
Katie Falzone	Senior Vice President of Finance	no data	Veri yok	Veri yok
Michael Mina	Chief Medical Officer	less than a year	Veri yok	Veri yok

2.3yrs

Ortalama Görev Süresi

51.5yo

Ortalama Yaş

Deneyimli Yönetim: IVVD 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2.3 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Terrance McGuire	Independent Director	5.5yrs	US$84.46k	Veri yok
Kevin McLaughlin	Independent Director	1.9yrs	US$101.61k	0.018% $ 88.0k
Marc Elia	Independent Chairperson of the Board	3.8yrs	US$125.96k	Veri yok
Ajay Royan	Independent Director	1.1yrs	US$110.16k	Veri yok
Paul B. Bolno	Director	less than a year	US$134.35k	Veri yok
Tamsin Berry	Independent Director	3.8yrs	US$87.96k	0% $ 0

2.9yrs

Ortalama Görev Süresi

50yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: IVVD 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilmiyor ( 2.9 yıllık ortalama görev süresi), bu da yeni bir yönetim kurulu olduğunu gösteriyor.

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2026/04/12 16:45
Gün Sonu Hisse Fiyatı	2026/04/10 00:00
Kazançlar	2025/12/31
Yıllık Kazançlar	2025/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Invivyd, Inc. 6 Bu analistlerden 4, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Thomas Shrader	BTIG
Joshua Schimmer	Cantor Fitzgerald & Co.
Jason Kolbert	D. Boral Capital LLC.

Invivyd Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Invivyd, Inc., Annual General Meeting, May 19, 2026

Invivyd, Inc. Appoints Michael Mina, M.D., Ph.D. As Chief Medical Officer

Invivyd Appoints Paul B. Bolno, M.D. to Its Board of Directors

Invivyd, Inc. Appoints Kristie Kuhl as Chief Communications Officer

Invivyd, Inc., Annual General Meeting, May 20, 2025

Invivyd, Inc. Appoints Ajay Royan, to Its Board of Directors

Recent updates

Invivyd, Inc Announces Progress in Revolution Program and Advancement of Novel Measles Monoclonal Antibody Candidate VMS063 for Treatment and Prevention of Measles

Invivyd, Inc., Annual General Meeting, May 19, 2026

Invivyd: A Logical Bull Thesis With A Major Catalyst Approaching

Invivyd, Inc. Appoints Michael Mina, M.D., Ph.D. As Chief Medical Officer

Invivyd Aligns with the U.S. Fda on Liberty, A Phase 3 Trial to Evaluate the Safety of Vyd2311 Antibody Versus Mrna Covid Vaccine, and to Characterize the Safety and Immunology of Antibody and Vaccine

Invivyd, Inc.'s (NASDAQ:IVVD) 26% Share Price Plunge Could Signal Some Risk

Invivyd and SPEAR Study Group Announce Plan for Phase 2 Study of VYD2311 for Treatment of Long COVID and COVID Vaccine-Injured Individuals to Commence Mid-2026

Optimistic Investors Push Invivyd, Inc. (NASDAQ:IVVD) Shares Up 27% But Growth Is Lacking

Invivyd, Inc. Announces Selection of Potential Best-In-Class RSV Antibody Candidate VBY329

Invivyd, Inc. has completed a Follow-on Equity Offering in the amount of $124.9994 million.

Invivyd, Inc.'s (NASDAQ:IVVD) Price Is Right But Growth Is Lacking After Shares Rocket 31%

Invivyd, Inc. Announces U.S. Food and Drug Administration Clearance of Investigational New Drug Application and Provide Feedback to Advance the Company's Revolation Clinical Program

Invivyd Appoints Paul B. Bolno, M.D. to Its Board of Directors

Invivyd, Inc. Appoints Kristie Kuhl as Chief Communications Officer

SPEAR Study Group to Present its Recommended Long COVID Antibody Study Design Featuring Invivyd's VYD2311 At Recover-TLC Workshop

Invivyd, Inc. has completed a Follow-on Equity Offering in the amount of $49.997866 million.

Why Investors Shouldn't Be Surprised By Invivyd, Inc.'s (NASDAQ:IVVD) 31% Share Price Plunge

Invivyd, Inc. has filed a Follow-on Equity Offering.

Invivyd, Inc. Announces Continued Neutralizing Activity of PEMGARDA®? (Pemivibart) and VYD2311 Against Currently Dominant SARS-CoV-2 Variant XFG

Invivyd, Inc. Aligns with U.S. FDA on Rapid Pathway to Full Approval of Vaccine Alternative Monoclonal Antibody VYD2311 to Protect American Adults and Adolescents from COVID-19

Invivyd and Leading Researchers Form SPEAR (Spike Protein Elimination and Recovery) Study Group to Assess the Effects of Monoclonal Antibody Therapy for Long Covid and Covid-19 Post-Vaccination Syndrome

Invivyd, Inc. Announces Positive Full Phase 1/2 Clinical Data for VYD2311, A Next Generation COVID-19 Monoclonal Antibody for Potential Use as a Non-Vaccine Preventative and for Treatment of Active Infection

Invivyd Announces Publication of Landmark CANOPY Phase 3 Pemivibart Clinical Trial

Invivyd, Inc. Announces Inclusion of PEMGARDA (Pemivibart) in National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology for B-Cell Lymphomas

Invivyd, Inc. Commends FDA Focus on Contemporary Evidence in Evaluating Medical Interventions to Prevent Covid-19

Invivyd, Inc. Files Citizen Petition Urging FDA to Focus on Monoclonal Antibodies for Endemic-Virus-Era COVID-19 Prevention, and to Re-Assess COVID-19 Vaccine Efficacy

Invivyd Announces New Pipeline Discovery Program Focused on Monoclonal Antibody Treatment for Measles

Invivyd Receives a Deficiency Letter from the Nasdaq Listing Qualifications Department of the Nasdaq Stock Market

Pemivibart And Next-Generation VYD2311 Will Empower Market Expansion By 2025

Invivyd, Inc., Annual General Meeting, May 20, 2025

Invivyd, Inc. Appoints Ajay Royan, to Its Board of Directors

Invivyd, Inc. Auditor Raises 'Going Concern' Doubt

Invivyd, Inc. Announces Continued Neutralizing Activity of PEMGARDA™? (Pemivibart) Against Currently Dominant SARS-CoV-2 Variant LP.8.1

I See The Bull Case For Invivyd, But I'm Not Married To It

Invivyd Announces Positive Phase 1/2 Clinical Data for VYD2311, a Monoclonal Antibody Designed to be a Superior Alternative to COVID-19 Vaccination for the Broad Population

Will Invivyd (NASDAQ:IVVD) Spend Its Cash Wisely?

Invivyd Provides Another Positive SARS-CoV-2 Variant Data Analysis to Satisfy U.S. FDA’s Gating Request for Completing Its Review of EUA Request for PEMGARDA™ (pemivibart) for the Treatment of Mild-to-Moderate COVID-19 in Certain Immunocompromised Patients

Invivyd, Inc. Announces Continued Neutralizing Activity of PEMGARDA (pemivibart) Against Dominant SARS-CoV-2 Variant XEC

Invivyd, Inc. Receives Non-Compliance Letter from Nasdaq Regarding Minimum Bid Price Requirement

Invivyd, Inc. Announces Resignation of Sara Cotter from the Board of Directors

Invivyd Announces Preprints Conveying CANOPY Phase 3 Clinical Trial Data Including Long-Term Protection Versus Recent JN.1 Sublineages at Low Residual Titers

Invivyd, Inc. Withdraws Financial Guidance for the Year 2024

Invivyd Phase 3 Long-Term Exploratory Clinical Efficacy Data Shows Pemgarda™ (Pemivibart) Provided Substantial Protection from Symptomatic Covid-19 Versus Placebo over Six Months of Follow-Up, with No Additional Doses, in Immunocompetent Participants

Invivyd, Inc. Announces U.S. FDA Has Updated the PEMGARDA EUA Fact Sheet with Accurate SARS-CoV-2 Variant Sensibility and PEMGARDA Activity Data

Invivyd, Inc. Doses First Participants in Phase 1 Clinical Trial of VYD2311, A Next Generation Monoclonal Antibody Candidate for COVID-19

Invivyd Announces PEMGARDA™ (pemivibart) Demonstrated 84% Relative Risk Reduction in Symptomatic COVID-19 Compared to Placebo in an Exploratory Analysis from Ongoing CANOPY Phase 3 Clinical Trial

Here's Why We're Watching Invivyd's (NASDAQ:IVVD) Cash Burn Situation

Invivyd Announces General Alignment with U.S. FDA on A Repeatable, Expedient Emergency Use Authorization Pathway for the Prevention and Treatment of Symptomatic COVID-19, Based on Compact Clinical Programs to Establish Safety and Immunobridging for Serial Monoclonal Antibodies

Invivyd, Inc. Announces Management Changes

Invivyd, Inc. Elects Two New Independent Members to its Board of Directors

Forecast to breakeven in 2026

Invivyd, Inc. to Pursue Rapid Immunobridging Pathway to Potential EUA for Treatment of COVID-19 in Moderately to Severely Immunocompromised People, Based on U.S. FDA Feedback

Invivyd, Inc., Annual General Meeting, May 21, 2024

Invivyd, Inc. Receives Healthcare Common Procedure Coding System Reimbursement Codes from the U.S. Centers for Medicare & Medicaid Services Covering Pemgarda

Invivyd, Inc. Announces CEO Changes

New minor risk - Profitability

No longer forecast to breakeven

Consensus revenue estimates fall by 13%

Invivyd, Inc. Provides Earnings Guidance for the Year 2024

Forecast breakeven date moved forward to 2025

Consensus revenue estimates increase by 64%

Is Invivyd (NASDAQ:IVVD) In A Good Position To Invest In Growth?

Invivyd Announces FDA Authorization for Emergency Use of PEMGARDA™ (Formerly VYD222) for Pre-exposure Prophylaxis (PrEP) of COVID-19

New minor risk - Shareholder dilution

Forecast to breakeven in 2026

Invivyd, Inc. has filed a Follow-on Equity Offering in the amount of $75 million.

Invivyd, Inc. Announces Positive Initial Results from Ongoing CANOPY Phase 3 Pivotal Clinical Trial Investigating VYD222 for the Prevention of COVID-19

We're Keeping An Eye On Invivyd's (NASDAQ:IVVD) Cash Burn Rate

Invivyd Announces Dosing of First Participant in CANOPY Phase 3 Pivotal Clinical Trial Investigating VYD222 for the Prevention of Symptomatic COVID-19